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ABSTRACT 
 
Mutations in the quinolone resistance-determining regions (QRDR) in chromosomal gyrA and parC genes 
and fluoroquinolone susceptibility profiles were investigated in quinolone-resistant Enterobacteriaceae 
isolated from community and hospitalized patients in the Brazilian Southeast region. A total of 112 nalidixic 
acid-resistant enterobacterial isolates collected from 2000 to 2005 were investigated for mutations in the 
topoisomerases genes gyrA and parC by amplifying and sequencing the QRDR regions. Susceptibility to 
fluoroquinolones was tested by the agar dilution method. Amongst the 112 enterobacterial isolates, 81 
(72.3%) were resistant to ciprofloxacin and 5 (4.5%) showed reduced susceptibility. Twenty-six (23.2%) 
were susceptible to ciprofloxacin. Several alterations were detected in gyrA and parC genes. Escherichia 
coli isolates (47.7%) showed double mutations in the gyrA gene and a single one in the parC gene. Two 
unusual aminoacid substitutions are reported, an Asp87-Asn in a Citrobacter freundii isolate with reduced 
susceptibility to fluoroquinolones and a Glu84-Ala in one E. coli isolate. Only a parC gene mutation was 
found in fluoroquinolone-susceptible Enterobacter aerogenes. None of the isolates susceptible to 
ciprofloxacin presented mutations in topoisomerase genes. This comprehensive analysis of QRDRs in gyrA 
and parC genes, covering commonly isolated Enterobacteriaceae in Brazil is the largest reported up to now. 
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INTRODUCTION 
 
Fluoroquinolones have been frequently prescribed as 
empirical therapy against most hospital and community 
infections due to increased appearance of multiple drug 
resistant Gram-negative pathogens and to the disease severity 
(2, 8, 22). In countries with extensive clinical use of 
quinolones, fluoroquinolone resistance has been a problem in 
clinical medicine for its limiting of available agents in the 
treatment of many types of infection (1, 7, 15, 23).  
Brazil has one of the highest rates of resistance to 
quinolones among Latin American countries. A report from the 
SENTRY Antimicrobial Surveillance Program revealed that 
resistance to nalidixic acid was higher in Latin American
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(15%) than in North America (6.3%), being as high as 50% in 
Mexico and 33.6% in Brazil (1). Brazilian investigators 
confirmed the information reporting that the significant 
increase in resistance to quinolones detected in Brazilian 
medical centers between 2002-2006 may be related to 
increased drug use in community acquired infections and 
hospital-wide antibiotic pressure (9, 18). 
Fluoroquinolone resistance has been associated with DNA 
gyrase and topoisomerase IV alterations for both Gram-
negative and Gram-positive organisms. Structural 
topoisomerase changes reducing the affinity of this enzyme to 
fluoroquinolones are caused by mutations in the quinolone 
resistance-determining regions (QRDR) of gyrA and parC 
genes (14, 21). Other mechanisms involve mutations affecting 
the intracellular accumulation of fluoroquinolones in the cell 
wall (19) and the expression of outer membrane proteins 
(OMP) leading to reduced entry of antibiotics (17, 24). Three 
additional mechanisms of quinolone resistance have been 
reported. These refer to the presence of Qnr proteins, which 
protect type II topoisomerases from quinolones (10, 11, 16); of 
a variant aminoglycoside acetyltransferase, Aac(6’)-Ib-cr, that 
modifies ciprofloxacin (20) and of active drug efflux pumps 
QepA and OqxAB, belonging to the major facilitator 
superfamily (MFS) transporters (6, 27). Topoisomerase 
mutations have not been, up to now, systematically 
investigated and explored in clinical isolates from Brazil, 
except in a report on ciprofloxacin susceptible E. coli (5).  
The objective of this study was to assess the presence of 
mutations in the QRDR of chromosomal gyrA and parC genes 
and fluoroquinolone susceptibility profile in quinolone-
resistant Enterobacteriaceae isolated from community and 
hospital patients in the Brazilian Southeast region. 
 
MATERIALS AND METHODS 
 
Bacterial isolates and susceptibility testing 
From 2000 to 2005, 112 clinical non-duplicate nalidixic 
acid- resistant Enterobacteriaceae isolates were obtained from 
outpatients (n=91) and inpatients (n=21) referred to 
laboratories located in the city of Juiz de Fora (State of Minas 
Gerais ) and Ribeirão Preto (State of São Paulo ). All species 
were identified both by conventional techniques and by 
MiniAPI, a semi-automatized assay (bioMérieux, Marcy 
l’Etoile, France). Susceptibility to fluoroquinolones was tested 
by the agar dilution method with E. coli ATCC 25922 as a 
control reference in MIC determinations. Susceptibility and 
resistance breakpoints were those defined by the Clinical and 
Laboratory Standards Institute (3).  
 
Detection of mutations in the topoisomerase genes 
DNA extraction and PCR analysis were performed as 
described elsewhere using sets of primers designed for 
amplification and sequencing of topoisomerase genes (10). 
DNA was amplified using an initial denaturation step of 5 min 
at 94oC, followed by 30 cycles consisting of 1 min at 94oC, 1 
min at the annealing temperature of 55oC and 1 min at 72oC, 
and a final extension step of 10 min at 72oC. Amplified DNA 
products were resolved by electrophoresis in 1% agarose gels 
and staining with ethidium bromide. PCR products were 
purified for sequencing by GFXTM PCR (GE Healthcare, 
Buckinghamshire, UK). The forward and reverse strands were 
sequenced in MegaBACE 1000 (GE Healthcare) with the same 
PCR primer sets. Raw sequences were reviewed by visual 
inspection using the software Chromas v.1.45 (32-bit) 
(Technelysium Pty. Ltd). QRDR nucleotide sequences in gyrA 
and parC genes from each of the 112 isolates were compared 
with the respective reference sequences in the GenBank 
database (accession numbers from AF052253 to AF052260).  
 
RESULTS AND DISCUSSION 
 
Species distribution among the 112 Enterobacteriaceae 
isolates was: Escherichia coli (n=65), Klebsiella pneumoniae 
(n=21), Klebsiella oxytoca (n=12), Enterobacter cloacae (n=6), 
Citrobacter freundii (n=2), Providencia stuartii (n=2), Serratia 
marcescens (n=2), Enterobacter aerogenes (n=1) and Proteus 
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mirabilis (n=1). Twenty-three percent of the 112 nalidixic acid-
resistant isolates were susceptible to ciprofloxacin and/or 
levofloxacin (MIC ≤ 1 µg/mL).  
Table 1 summarizes codon numbers and the 
corresponding alteration detected in the gyrA and parC genes 
of fluoroquinolone-resistant and susceptible clinical isolates 
included in the study and the corresponding MIC values. All 
Enterobacteriaceae isolates had amplification products. 
 
Table 1. Fluoroquinolone MIC values, and alterations detected in the gyrA and parC genes of Enterobacteriaceae isolates 
MIC (µg/mL) †‡  Species 
 
Number 
of isolates CIP NOR OFL LVX gyrA position parC position 
Citrobacter freundii  1 32 64 64 32 Thr83 Ile   Asp87Asn   
 1 0.25 0.5 1 0.5 Thr83 Ile      
Enterobacter aerogenes 1 0.5 1 0.5 0.25     Cys107Trp
Enterobacter  cloacae  1 16 64 16 8 Ser83Phe Asp87Asn Ser80Ile   
 2 32-64 64-128 16-64 8-64 Ser83Phe Asp87Asn    
 1 64 >128 32 32 Ser83Tyr Asp87Ala    
 1 0,125 1 2 0,5 -------------------- No mutation ----------------- 
 1* 2 1 1 0,5 -------------------- No mutation ----------------- 
Escherichia coli  4 32 - >128 >128 64-128 16-128 Ser83Leu  Asp87Asn Ser80Ile Glu84Gly  
 1 32 32 >128 16 Ser83Leu  Asp87Asn Ser80Ile Glu84Ala  
 1 16 128 64 32 Ser83Leu  Asp87Asn Ser80Ile Glu84Lys  
 1 64 128 128 64 Ser83Leu  Asp87Asn Ser80Arg   
 31 2->128 8 - >128 4-128 2-64 Ser83Leu  Asp87Asn Ser80Ile   
 4 2 4 1-4 1-2 Ser83Leu  Asp87Tyr Ser80Ile   
 1 1 4 2 1 Ser83Leu Asp87Gly Gly78Cys   
 1 8 16 16 8 Ser83Leu Asp87Gly Ser80Ile   
 7 8-64 16-128 16-64 4-64 Ser83Leu  Asp87Asn  Glu84Lys  
 1 1 2 4 2 Ser83Leu Asp87Asn   Cys107Trp
 1 4 8 8 4 Ser83Leu   Ser80Arg   
 3 0.06-1 0.5-4 0.12-4 0.12- 2  Asp87Gly    
 4 0.03-8 0.5-64 0.5-8 0.25-8 Ser83Leu      
 5 0.03-1 0.03-4 0.06-2 0.03-4 -------------------- No mutation ----------------- 
Klbsiella oxytoca 1 32 64 64 32 Thr83Ile Asp87Tyr Ser80Arg Pro91Ser  
 6 16-32 64-128 16-32 8-16 Thr83Ile Asp87His Ser80Ile Pro91Ser  
 1 32 64 64 32 Thr83Ile Asp87Tyr  Pro91Ser  
 4 8-16 16-64 8-16 2-8 Thr83Ile Asp87His Ser80Ile   
Klebsiella pneumoniae 1 16 64 32 16 Ser83Phe Asp87Ala Ser80Ile   
 4 4-8 16-64 4-16 4-8 Ser83Ile  Ser80Ile   
 1 128 >128 128 128 Ser83Phe  Ser80Ile   
 8 0.25-4 1-16 1-8 0.5-4 Ser83Phe     
 3 4-8 16-32 4-16 2-8 Ser83Tyr     
 1 1 8 4 2  Asp87Tyr    
 3 0.5-1 0.5-8 0.125-4 0.06-1 -------------------- No mutation ----------------- 
Proteus mirabilis 1 1 8 1 1 Ser83Phe     
Providencia stuartii 1 64 128 64 128 Ser83Ile Glu87Gly    
 1 32 >128 16 16 Ser83Arg     
Serratia marcescens 2 8-16 64-128 16-32 16 Ser83Ile         
* qnrA gene present 
† CIP, ciprofloxacin, NOR, norfloxacin; OFL, ofloxacin; LVX, levofloxacin 
‡ Susceptibility (≤ value) and resistance (≥ value) breakpoints defined by CLSI (2011): 4 µg/mL and 16 µg/mL for norfloxacin, 2 µg/mL and 8 µg/mL for 
levofloxacin and ofloxacin, 1 µg/mL and 4 µg/mL for ciprofloxacin. 
 
According to Ruiz (21), codons 83 and 87 in gyrA and 
codons 80 and 84 in parC gene display the most common 
alterations in clinical isolates. In addition, expression of high-
level fluoroquinolone resistance in Enterobacteriaceae requires 
the presence of multiple mutations in gyrA and/or parC genes.  
Topoisomerase genes in nine isolates susceptible to 
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ciprofloxacin (MICs ≤ 1 µg/mL) did not show mutations. 
However, one E. cloacae exhibiting decreased susceptibility to 
fluoroquinolones (MIC 2 µg/mL) and no mutation in 
topoisomerase genes had a previously detected qnrA gene (4, 
12).  
The majority of Enterobacteriaceae isolates in the study 
(91%) showed a QRDR region with mutations in codons 83 
and/or 87 of the gyrA gene. Twelve different types of 
mutations were found amongst the collection analyzed. They 
were Thr83-Ile and Asp87-Asn in C. freundii, Ser83-Phe, 
Ser83-Tyr, Asp87-Asn and Asp87-Ala in E. cloacae, Ser83-
Leu, Asp87-Asn, Asp87-Tyr and Asp87-Gly in E. coli, Thr83-
Ile, Asp87-Tyr and Asp87-His in K. oxytoca, Ser83-Phe, 
Ser83-Tyr, Asp87-Ala and Asp87-Tyr in K. pneumoniae, 
Ser83-Phe in P. mirabilis, Ser83-Ile, Ser83-Arg and Glu87-Gly 
in P. stuartii and Ser83-Ile in S. marcescens (Table 1). All 
fluoroquinolone resistant E. coli isolates had the usual Ser83-
Leu substitution in gyrA gene but according to Vila et al. (25), 
the additional mutation in codon 87 is associated with an 
increased fluoroquinolone resistance. This was confirmed by 
the results for E. coli (Table 1), as four of the isolates with a 
single alteration, Ser83-Leu, had MICs ≤ 8 µg/mL for 
ciprofloxacin. However, the isolates with an additional and 
common mutation in codon 87(Asp87-Asn), as shown by 
91.6% of the samples, had higher ciprofloxacin MICs ≥ 8 
µg/mL. Eleven K. pneumoniae isolates with a single alteration 
in codon 83 also showed ciprofloxacin MICs < 8 µg/mL. Three 
E. coli isolates and one K. pneumoniae having a single 
alteration in codon 87, Asp87-Gly or Asp87-Tyr, had MIC ≤ 1 
µg/mL for ciprofloxacin.  
Codons 78, 80, 84 and 107 showed alterations in the 
QRDR of the parC gene. The replacements were Gly78-Cys, 
Ser80-Ile, Ser80-Arg, Glu84-Gly, Glu84-Ala, Glu84-Lys, 
Cys107-Trp in E. coli, Ser80-Ile in E. cloacae, Cys107-Trp in 
E. aerogenes, Ser80-Arg, Ser80-Ile, Pro91-Ser, in K. oxytoca 
and Ser80-Ile in K. pneumoniae. Analysis of the data presented 
in Table 1, did not indicate that these changes could be by 
themselves responsible for the difference in fluoroquinolone 
MIC values among the different isolates. 
A different substitution, not reported to date, at codon 84 
of the parC gene (glutamine replaced by alanine) was exhibited 
by one E. coli isolate with Ser83-Leu, Asp87-Asn and Ser80-
Ile replacements. C. freundii, P. mirabilis, P. stuartii, S. 
marcescens isolates did not present mutations in parC gene. 
Substitutions in gyrA and parC genes were found in 
95.8% of fluoroquinolones-resistant E. coli isolates in this 
study. According to Table 1, 47.7% of E. coli isolates showed 
substitutions: Ser83-Leu and Asp87-Asn in gyrA gene and 
Ser80-Ile in parC gene, while six isolates (9.2%) (CIP MIC 
≥16 µg/mL) had Ser83-Leu and Asp87-Asn substitutions in 
gyrA gene, and Ser80-Ile and Glu84-Gly, Glu84-Ala or Glu84-
Lys in parC gene. Another uncommon substitution (serine by 
arginine) at codon 80 in parC gene was observed in one E. coli 
isolate. In general, a substitution in Ser-83 is sufficient to 
generate a high level of resistance to nalidixic acid, whereas a 
second mutation at Asp-87 in gyrA gene may play a 
complementary role in the development of high levels of 
ciprofloxacin resistance. 
According to Weigel et al. (26), C. freundii isolates with 
reduced susceptibility to fluoroquinolones exhibited Thr83 to 
Ile mutations as a result of C-to-T substitutions at the 
nucleotide 248th position in gyrA. In one C. freundii isolate, in 
this study, another different substituted amino acid was 
detected in gyrA gene, Asp87-Asn instead of glycine, which to 
our knowledge has not been described so far. Although rarely 
reported in the literature, alterations in codon 83 (serine for 
isoleucine) and 87 (asparagine for alanine or tyrosine) in gyrA 
gene were detected in K. pneumoniae isolates (4, 26). No such 
alteration in the parC gene of the ciprofloxacin susceptible K. 
pneumoniae was found. 
Just one alteration, Thr83-Ile, in gyrA gene was reported 
by Weigel et al. (26) in ciprofloxacin resistant K. oxytoca. 
Additional substitutions were found in this study, Asp87-Tyr in 
2 isolates and Asp87-His in 10 others having MICs for 
ciprofloxacin of 32 µg/mL and 8 -16 µg/mL respectively. All 
fluoroquinolone resistant K. oxytoca isolates had mutations 
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detected in gyrA and parC genes, the most frequent being 
Ser80-Ile and Pro91-Ser. The alterations found in P. stuartii 
and S. marcescens isolates were the same reported by Weigel 
et al. (26). 
It has been shown that the primary quinolone target in 
Enterobacteriaceae is gyrase and topoisomerase IV enzymes, 
since mutations in parC or parE are observed only in addition 
to the ones in DNA gyrase (7). However, the only 
fluoroquinolone susceptible E. aerogenes tested had just one 
mutation in codon 107 in parC gene, Cys107-Trp. 
A diversity of alterations has been found in gyrA and parC 
genes, but there was not a clear correlation between frequency 
of distribution of each alteration type and fluoroquinolone MIC 
values, which varied from 2 to >128 µg/mL for ciprofloxacin, 
from 4 to 128 µg/mL for ofloxacin and from 2 to 64 µg/mL for 
levofloxacin.  
Consistent with previous studies, low-level 
fluoroquinolone resistance in E. coli is associated with a single 
alteration in the GyrA protein while high-level resistance 
required double mutations (2, 23). However, in all other species 
in this study, there were isolates exhibiting a single alteration in 
gyrA gene and high-level fluoroquinolone resistance. Other 
mechanisms implicated in fluoroquinolone resistance, which 
might be responsible for the differences in MICs values for 
fluoroquinolones observed among the isolates with the same 
types of mutation in all genes were not considered in the 
present study. Changes in permeability and active efflux are 
mechanisms that cannot be excluded and may enhance 
development of resistance and contribute to the selection of 
fluoroquinolone-resistant isolates in the course of treatments 
with these antibiotics. Furthermore, the presence of one or 
more related clones in the collection studied was not 
determined by molecular typing methodologies. 
In conclusion, this study documented alterations in the 
QRDR segments of gyrA and parC genes in ciprofloxacin 
susceptible and resistant Enterobacteriaceae recovered from 
clinical specimens in the Southeast region of Brazil. The 
alterations reported are the most detailed in the QRDR in gyrA 
and parC genes and include the ones in commonly isolated 
Enterobacteriaceae. Additional data on topoisomerase 
sequences and mutations associated with fluoroquinolone 
resistance in clinical isolates of diversified Enterobacteriaceae 
species was also provided.  
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